Current filters:


Bristol-Myers Squibb refocuses R&D strategy

Bristol-Myers Squibb refocuses R&D strategy


US drug major Bristol-Myers Squibb says it is “evolving its strategic focus in R&D to ensure continued…

Anti-viralsBristol-Myers SquibbDiabetesManagementNeurologicalOncologyPharmaceuticalResearch

Vertex and Bristol-Myers to trial VX-135 and daclatasvir for hep C; B-MS names new R&D head


US drugmaker Vertex Pharmaceuticals (Nasdaq: VRTX) has entered into a non-exclusive agreement with pharma…

Anti-viralsBristol-Myers SquibbdaclatasvirManagementPharmaceuticalResearchVertexVX-135

Pilot project for HIV/AIDS drug management supported by PAHO/WHO and the Global Fund may expand to other countries


Three Latin American countries - Guatemala, Honduras, and the Dominican Republic - are working to strengthen…

Anti-viralsGenericsHealthcareManagementPharmaceuticalSouth America

Briefs: Roche deal with Chiasma; Vasella payout; FDA priority review for dolutegravir


Swiss drug major Roche (ROG: SIX) has entered into an agreement to develop and commercialize privately…

Anti-viralsdolutegravirGlaxoSmithKlineLicensingManagementNovartisOctreotide AcetatePharmaceuticalRare diseasesRegulationRocheViiV Healthcare

New executive director of the Global Fund outlines ambitious agenda


Mark Dybul yesterday took charge as executive director of the Global Fund to Fight AIDS, Tuberculosis…

Anti-viralsAntibiotics and Infectious diseasesFinancialManagementPharmaceuticalTropical diseases

Back to top